Our integrated team of experts has advanced therapies across multiple respiratory diseases with a track record of delivering hits, leads, and pre-clinical candidates. Eurofins Discovery’s expertise is key when your team is working on respiratory diseases that are the leading cause of disability worldwide, including asthma, lung cancer, COPD, acute lower respiratory tract infection, tuberculosis, and, most recently, COVID-19.
The lungs are constantly exposed to toxic agents resulting from pollution, tobacco smoke, and combustion of biomass fuel, as well as harmful particles, chemicals, and infectious agents present in ambient air. Chronic respiratory diseases are rarely curable, therefore discovering novel therapies could have an enormous impact on decreasing the global burden of these disorders.
Our scientists offer innovative approaches and solutions to your respiratory disease programs, and will help you customize your screening cascades to fit your specific needs. Eurofins Discovery is committed to partnering with our clients discovering novel therapies for respiratory drugs from target identification through to pre-clinical candidate selection.
Eurofins Discovery’s Respiratory Diseases Capabilities
Features
Features
Questions? Contact Us
You can easily get in touch with a Eurofins Discovery Expert or get help from our Customer Service team. Reach out with questions, or to discuss your specific discovery challenges.
